Bioventus (BVS) – Globe Newswire
-
Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results
-
Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024
-
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
-
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
-
Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole
-
Bioventus Names Robert Claypoole as President and Chief Executive Officer
-
Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis
-
Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance
-
Bioventus to Report Third Quarter of Fiscal Year 2023 Financial Results on November 7, 2023
-
Bioventus to Present at the Cantor Global Healthcare Conference
-
Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
-
Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance
-
Bioventus to Present at the Canaccord Genuity 43rd Annual Global Growth Conference
-
Bioventus to Report Second Quarter of Fiscal Year 2023 Financial Results on August 8, 2023
-
Bioventus Completes Divestiture of its Wound Business
-
Bioventus Reports First Quarter Financial Results
-
Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023
-
Bioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023
-
Bioventus Announces Divestiture of its Wound Business
-
Bioventus Announces CEO Leadership Change
-
Bioventus Reports Fourth Quarter and Full-Year 2022 Financial Results
-
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
-
Bioventus Reschedules Reporting of Fourth Quarter Fiscal Year 2022 Financial Results to March 31, 2023
-
Bioventus to Report Fourth Quarter of Fiscal Year 2022 Financial Results on March 30, 2023
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Southwest Airlines, Y-mAbs, Bioventus, and ESS and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm
-
Bioventus Enters into Settlement Agreement to Preserve Maximum Optionality – Up To $350mm of Potential Liability Reduction and a Release of Future Claims related to the CartiHeal Acquisition
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Southwest Airlines, Y-mAbs, Bioventus, and ESS and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bioventus, ESS, IBM, and FATE and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bioventus, ESS, IBM, and FATE and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm
-
Bioventus to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Bioventus Issues Revised Third Quarter Results; Updates Full-Year 2022 Financial Guidance
-
Bioventus Files for Extension to File Form 10-Q for the Period Ended October 1, 2022
-
Bioventus Reports Third Quarter Results; Updates Full-Year 2022 Financial Guidance
-
Bioventus to Report Third Quarter of Fiscal Year 2022 Financial Results on November 8, 2022
-
Bioventus to Showcase Full Orthobiologics and Ultrasonic Portfolio at NASS in Chicago
-
Bioventus to Present at the Morgan Stanley Global Healthcare Conference
-
Bioventus Reports Second Quarter Results; Updates Full-Year 2022 Financial Guidance
-
Bioventus Receives FDA 510(k) Clearance for SonaStar Elite
-
Bioventus to Report Second Quarter of Fiscal Year 2022 Financial Results on August 11, 2022
-
Bioventus Completes CartiHeal Acquisition
-
Bioventus Amends CartiHeal Acquisition Structure
-
Bioventus Reports First Quarter Results; Reaffirms Full-Year 2022 Financial Guidance
-
Bioventus Cancels Proposed $415 Million Offering of Senior Notes; Reaffirms Full-Year 2022 Financial Guidance
-
Bioventus Agrees to Nationwide Contract with Cigna Commercial Plans for DUROLANE® and GELSYN-3® for Knee Osteoarthritis
-
Bioventus Announces Preliminary First Quarter Net Sales and Adjusted EBITDA
-
Bioventus Announces $415 Million Offering of Senior Notes
Back to BVS Stock Lookup
